Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks

Abstract

IDH-mutant glioblastoma is classified by the 2016 CNS WHO as a group with good prognosis. However, the actual number of cases examined in the literature is relatively small. We hypothesize that IDH-mutant glioblastoma is not a uniform group and should be further stratified.

Document Details

Document Type
Pub Defense Publication
Publication Date
May 01, 2019
Source ID
10.1093/noajnl/vdz015

Entities

People

  • Aden Ka-yin Chan
  • Ho-keung Ng
  • Hong Chen
  • Houtan Noushmehr
  • Johnny Sheung Him Kwan
  • Kay Ka-wai Li
  • Rui Ryan Yang
  • Shaz Cheng
  • Tathiane M. Malta
  • Wai Sang Poon
  • Ying Mao
  • Zhi-feng Shi

Organizations

  • Fudan University
  • Henry Ford Health
  • National Cancer Institute
  • The Chinese University of Hong Kong
  • United States Department of Defense

Tags

Readers

  • Aerial Delivery - Logistics and Supply Chain Management.
  • Oncology and Biomarker-Based Cancer Detection.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.